


**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of  
**XU, et al.**

Application No.: 10/696,527

Filed: **September 29, 2003**

Title: **Timing and Duration of Administration of  
Adenosine A1/A2 Agonist for Cardioprotection**



Examiner: Not Yet Assigned

Art Unit: 1614

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

**February 9, 2004**

Date of Deposit

Signature

A handwritten signature in black ink, likely of the Commissioner for Patents, written over a horizontal line.

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. 1.56, 1.97 AND 1.98**

Mail Stop Patent Application  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

- ☒ (a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.



**THIS PAGE BLANK (USPTO)**

- ☐ (b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.
- ☐ (1) The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;
- ☐ (2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or
- ☐ (3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.

Respectfully submitted,



---

Jiang Lin, Reg. No. 51,065  
Agent for Applicant

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-3582  
Telefax (908) 231-2626


Aventis Docket No. USAV2001/0092 US CNT

**THIS PAGE BLANK (USPTO)**

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.



**THIS PAGE BLANK (USPTO)**



Please type a plus sign (+) inside this box → ☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **2** of **2**

### Complete if Known

Application Number	10/696,527
Filing Date	10-29-2003
First Named Inventor	XU
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	USAV2001/0092 - US - CNT

### OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		BUDDE, Jason M. et al., Comparative Study of AMP579 and Adenosine in Inhibition of Neutrophil-mediated Vascular and Myocardial injury During 24 h of Reperfusion, Cardiovascular Research; Vol. 47; No. 2; August 2000; pp. 295,302,304.	
		CLARK, Kenneth L. et al., AMP 579, a Novel Adenosine Agonist for the Treatment of Acute Myocardial Infarction, Cardiovascular Drug Reviews; Vol.18; No.3; 2000; pp. 183-210.	
		MERKEL, Linda et al., Pharmacological Characterization of AMP579, a Novel Adenosine A1/A2 Receptor Agonist and Cardioprotective, Drug Development Research; Vol. 45; No. 30; 1998; pp. 30-43.	
		McVEY, Matthew J. et al., Cardiovascular Pharmacology of the Adenosine A1/A2 Receptor Agonist AMP 579: Coronary Hemodynamic and Cardioprotective Effects in the Canine Myocardium, Journal of Cardiovascular Pharmacology; Vol. 33; No. 5; May 1999; pp. 703-710.	
		SMITS, G.J. et al., Cardioprotective Effects of the Novel Adenosine A1/A2 Receptor Agonist AMP 579 in a Porcine Model of Myocardial Infarction, Journal of Pharmacology and Experimental Therapeutics; Vol. 286; No. 2; August 1998; pp. 611-618.	
		SORBERA, L.A. et al., Treatment of Acute Myocardial Infarction Adenosine A1/A2 Agonist, Drugs of the Future; Vol. 25; No. 9; 2000; pp.900-906.	

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



**THIS PAGE BLANK (USPTO)**